Literature DB >> 19210173

Do benefits of earlier antiretroviral treatment initiation outweigh harms for individuals at risk for poor adherence?

R Scott Braithwaite1, Mark S Roberts, Matthew Bidwell Goetz, Cynthia L Gibert, Maria C Rodriguez-Barradas, Kimberly Nucifora, Amy C Justice.   

Abstract

Clinicians may defer antiretroviral treatment for patients with suboptimal adherence. We used a validated computer simulation of HIV disease progression to compare alternative treatment thresholds for patients with suboptimal adherence. Earlier treatment increased life expectancy across a wide adherence range (50%-100% of doses taken). Delaying treatment for patients with suboptimal adherence may not always be appropriate.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19210173      PMCID： PMC3032571          DOI： 10.1086/596768

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  12 in total

1.  Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda.

Authors:  R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

2.  A temporal and dose-response association between alcohol consumption and medication adherence among veterans in care.

Authors:  R Scott Braithwaite; Kathleen A McGinnis; Joseph Conigliaro; Stephen A Maisto; Stephen Crystal; Nancy Day; Robert L Cook; Adam Gordon; Michael W Bridges; Jason F S Seiler; Amy C Justice
Journal:  Alcohol Clin Exp Res       Date:  2005-07       Impact factor: 3.455

3.  Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation.

Authors:  R S Braithwaite; S Shechter; M S Roberts; A Schaefer; D R Bangsberg; P R Harrigan; A C Justice
Journal:  J Antimicrob Chemother       Date:  2006-10-05       Impact factor: 5.790

4.  Estimating the rate of accumulating drug resistance mutations in the HIV genome.

Authors:  R Scott Braithwaite; Steven Shechter; Chung-Chou H Chang; Andrew Schaefer; Mark S Roberts
Journal:  Value Health       Date:  2007 May-Jun       Impact factor: 5.725

5.  Estimating the proportion of patients infected with HIV who will die of comorbid diseases.

Authors:  R Scott Braithwaite; Amy C Justice; Chung-Chou H Chang; Jennifer S Fusco; Stephen R Raffanti; John B Wong; Mark S Roberts
Journal:  Am J Med       Date:  2005-08       Impact factor: 4.965

6.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

7.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

8.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, January 28, 2000 by the Panel on Clinical Practices for Treatment of HIV Infection.

Authors: 
Journal:  HIV Clin Trials       Date:  2000 Jul-Aug

9.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.

Authors:  M S Hirsch; F Brun-Vézinet; R T D'Aquila; S M Hammer; V A Johnson; D R Kuritzkes; C Loveday; J W Mellors; B Clotet; B Conway; L M Demeter; S Vella; D M Jacobsen; D D Richman
Journal:  JAMA       Date:  2000-05-10       Impact factor: 56.272

10.  Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection.

Authors:  Joan S Tucker; M Audrey Burnam; Cathy D Sherbourne; Fuan-Yue Kung; Allen L Gifford
Journal:  Am J Med       Date:  2003-05       Impact factor: 4.965
View more
  7 in total

1.  HIV Treatment in Resource-Limited Environments: Treatment Coverage and Insights.

Authors:  Amin Khademi; Denis Saure; Andrew Schaefer; Kimberly Nucifora; R Scott Braithwaite; Mark S Roberts
Journal:  Value Health       Date:  2015-11-12       Impact factor: 5.725

2.  Evaluating interventions to improve antiretroviral adherence: how much of an effect is required for favorable value?

Authors:  R Scott Braithwaite; David A Fiellin; Kimberly Nucifora; Kendall Bryant; Mark Roberts; Nancy Kim; Amy C Justice
Journal:  Value Health       Date:  2010-03-22       Impact factor: 5.725

3.  Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.

Authors:  Xavier Anglaret; Callie A Scott; Rochelle P Walensky; Eric Ouattara; Elena Losina; Raoul Moh; Jessica E Becker; Lauren Uhler; Christine Danel; Eugene Messou; Serge Eholié; Kenneth A Freedberg
Journal:  Antivir Ther       Date:  2012-07-18

4.  Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.

Authors:  Krishna P Reddy; Robert A Parker; Elena Losina; Travis P Baggett; A David Paltiel; Nancy A Rigotti; Milton C Weinstein; Kenneth A Freedberg; Rochelle P Walensky
Journal:  J Infect Dis       Date:  2016-11-03       Impact factor: 5.226

5.  When should antiretroviral therapy be started in HIV-positive persons?

Authors:  Caroline A Sabin
Journal:  F1000 Med Rep       Date:  2010-11-24

Review 6.  Modeling the cost-effectiveness of HIV treatment: how to buy the most 'health' when resources are limited.

Authors:  Jason Kessler; R Scott Braithwaite
Journal:  Curr Opin HIV AIDS       Date:  2013-11       Impact factor: 4.283

7.  Implementing tobacco use treatment guidelines in community health centers in Vietnam.

Authors:  Donna Shelley; Nancy VanDevanter; Charles C Cleland; Linh Nguyen; Nam Nguyen
Journal:  Implement Sci       Date:  2015-10-09       Impact factor: 7.327
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.